Selzentry, Celsentri(maraviroc)
Celsentri, Maraviroc, Selzentry (maraviroc) is a small molecule pharmaceutical. Maraviroc was first approved as Selzentry on 2007-08-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against C-C chemokine receptor type 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Maraviroc, Selzentry (discontinued: Selzentry)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Maraviroc
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SELZENTRY | ViiV Healthcare | N-022128 RX | 2007-08-06 | 2 products, RLD, RS |
| SELZENTRY | ViiV Healthcare | N-208984 RX | 2016-11-04 | 1 products, RLD, RS |
Show 1 discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MARAVIROC, SELZENTRY, VIIV HLTHCARE | |||
| 2024-04-30 | PED | ||
| 2023-10-30 | NPP | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
169 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 21 | 22 | 25 | 24 | 16 | 99 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 10 | 6 | 7 | 10 | 10 | 40 |
| Hiv | D006678 | — | O98.7 | 4 | 6 | 2 | 12 | 9 | 32 |
| Infections | D007239 | EFO_0000544 | — | 6 | 2 | 2 | 1 | 5 | 15 |
| Healthy volunteers/patients | — | — | — | 8 | 1 | — | 1 | — | 10 |
| Hepatitis c | D006526 | — | B19.2 | 1 | — | — | 3 | 1 | 5 |
| Hepatitis | D006505 | — | K75.9 | 1 | — | — | 3 | 1 | 5 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | — | — | 3 | 1 | 5 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | 1 | 3 | 1 | 5 |
| Hepatitis b | D006509 | — | — | — | — | — | 2 | 1 | 3 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv-1 | D015497 | — | — | — | 2 | 3 | — | 1 | 6 |
| Communicable diseases | D003141 | — | — | 3 | 2 | 2 | — | — | 6 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 5 | 1 | — | — | 5 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | 1 | 2 |
| Post-acute covid-19 syndrome | D000094024 | — | — | — | 2 | 1 | — | — | 2 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 1 | 1 | — | — | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | — | 1 | 1 | — | — | 1 |
| Aids dementia complex | D015526 | EFO_0002608 | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 2 | 4 | — | — | — | 4 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 3 | — | — | — | 4 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | 2 | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 1 | 2 | — | — | — | 2 |
| Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 1 | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 1 | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | — | 1 | — | — | — | 1 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 2 | — | — | — | 1 | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Mycobacterium avium complex | D015269 | — | — | 1 | — | — | — | — | 1 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | 1 | — | — | — | — | 1 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
| Immune reconstitution inflammatory syndrome | D054019 | — | D89.3 | — | — | — | — | 1 | 1 |
| Leukoencephalopathies | D056784 | — | R90.82 | — | — | — | — | 1 | 1 |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | — | — | — | 1 | 1 |
| Persistent infection | D000088562 | — | — | — | — | — | — | 1 | 1 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | — | 1 | 1 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | — | — | — | 1 | 1 |
| Second primary neoplasms | D016609 | — | — | — | — | — | — | 1 | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 1 | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Maraviroc |
| INN | maraviroc |
| Description | Maraviroc is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4,4-difluorocyclohexanecarboxylic acid and the primary amino group of (1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropylamine. An antiretroviral drug, it prevents the interaction of HIV-1 gp120 and chemokine receptor 5 (CCR5) necessary for CCR5-tropic HIV-1 to enter cells. It has a role as an antiviral drug, a chemokine receptor 5 antagonist and a HIV fusion inhibitor. It is an azabicycloalkane, an organofluorine compound, a member of triazoles and a monocarboxylic acid amide. |
| Classification | Small molecule |
| Drug class | antivirals; antivirals, chemokine receptor (CCR) antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 376348-65-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201187 |
| ChEBI ID | 63608 |
| PubChem CID | 3002977 |
| DrugBank | DB04835 |
| UNII ID | MD6P741W8A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,764 documents
View more details
Safety
Black-box Warning
Black-box warning for: Maraviroc, Selzentry
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,787 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use